# Qli5 Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/qli5-therapeutics

- Industry: Healthcare
- Headquarters: Dortmund, Germany
- Website: www.qli5tx.com
- Total disclosed funding: $12M
- Latest round: Series A (Jun 13, 2022)
- Investors on record: 3

## About

Based in Dortmund, Germany, QLi5 Therapeutics GmbH develops a new class of proteasome inhibitors. The company was co-founded by Prof. Robert Huber and Kiyean Nam. As of 2023, the company is headed by its CEO Martin Huber. In June 2022, Qli5 Therapeutics raised EUR 10 million in series A funding from returning investor Khanu Management, with participation from new investor Atinum Investment. The Series A funding values Qli5 Therapeutics GmbH at EUR 86.14 million post-money.

The company offers a proteasome inhibitor platform that can be expanded to various indications as well as has high selectivity and unique, non-covalent binding properties. It has a strong anti-tumor activity against multiple myeloma and solid tumors.

The company plan to use the June 2022 funding to advance its highly differentiated proteasome inhibitors to the start of clinical trials.

## Funding rounds

- Series A, Jun 13, 2022, $11M — Atinum Investment, Khanu Management
- Series A, Dec 13, 2021, $1.1M — SV Investment, Khanu Management

## Investors

- SV Investment (https://capitalatlas.ai/funds/sv-investment) — Series A
- Khanu Management (https://capitalatlas.ai/funds/khanu-management) — Series A
- Atinum Investment (https://capitalatlas.ai/funds/atinum-investment) — Series A